General and Administrative Expense of OptimizeRx Corp from 30 Jun 2011 to 30 Sep 2025

Taxonomy & unit: us-gaap: USD
Description: The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.
Summary: OptimizeRx Corp quarterly and annual General and Administrative Expense in USD history and change rate from 30 Jun 2011 to 30 Sep 2025.
OptimizeRx Corp General and Administrative Expense for the quarter ending 30 Sep 2025 was $14,386,000, a 7.2% increase year-over-year.
OptimizeRx Corp annual General and Administrative Expense for 2013 was $288,297, a 7% increase from 2012.
OptimizeRx Corp annual General and Administrative Expense for 2012 was $269,448, a 40% decline from 2011.
Source SEC data: View on sec.gov

General and Administrative Expense, Trailing 12 Months (USD)

General and Administrative Expense, Quarterly (USD)

General and Administrative Expense, YoY Quarterly Change (%)

General and Administrative Expense, Annual (USD)

General and Administrative Expense, YoY Annual Change (%)

OptimizeRx Corp Quarterly General and Administrative Expense (USD)

Period	TTM Value	Value	YoY Chg	Change %	Start Date	End Date	Report	Filed	Fiscal Year	Fiscal Period
Q3 2025		$14,386,000	+$961,000	+7.2%	01 Jul 2025	30 Sep 2025	10-Q	07 Nov 2025	2025	Q3
Q2 2025		$14,372,000	-$8,000	-0.06%	01 Apr 2025	30 Jun 2025	10-Q	08 Aug 2025	2025	Q2
Q1 2025		$14,364,000	-$1,802,000	-11%	01 Jan 2025	31 Mar 2025	10-Q	13 May 2025	2025	Q1
Q3 2024		$13,425,000	+$539,000	+4.2%	01 Jul 2024	30 Sep 2024	10-Q	07 Nov 2025	2025	Q3
Q2 2024		$14,380,000	+$2,171,000	+18%	01 Apr 2024	30 Jun 2024	10-Q	08 Aug 2025	2025	Q2
Q1 2024		$16,166,000	+$2,134,000	+15%	01 Jan 2024	31 Mar 2024	10-Q	13 May 2025	2025	Q1
Q3 2023		$12,886,000			01 Jul 2023	30 Sep 2023	10-Q	14 Nov 2024	2024	Q3
Q2 2023		$12,209,000			01 Apr 2023	30 Jun 2023	10-Q	15 Aug 2024	2024	Q2
Q1 2023		$14,032,000			01 Jan 2023	31 Mar 2023	10-Q	15 May 2024	2024	Q1
Q1 2014	$158,767	$89,264	-$129,530	-59%	01 Jan 2014	31 Mar 2014	10-Q	15 May 2014	2014	Q1
Q4 2013	$288,297	$81,715	-$153,795	-213%	01 Oct 2013	31 Dec 2013	10-K	31 Mar 2014	2013	FY
Q3 2013	$442,092	$94,753	+$31,545	+50%	01 Jul 2013	30 Sep 2013	10-Q	14 Nov 2013	2013	Q3
Q2 2013	$410,547	$56,465	-$645	-1.1%	01 Apr 2013	30 Jun 2013	10-Q	12 Aug 2013	2013	Q2
Q1 2013	$411,192	$218,794	+$141,744	+184%	01 Jan 2013	31 Mar 2013	10-Q	15 May 2014	2014	Q1
Q4 2012	$269,448	$72,080			01 Oct 2012	31 Dec 2012	10-K	31 Mar 2014	2013	FY
Q3 2012		$63,208	-$69,604	-52%	01 Jul 2012	30 Sep 2012	10-Q	14 Nov 2013	2013	Q3
Q2 2012		$57,110	-$43,836	-43%	01 Apr 2012	30 Jun 2012	10-Q	12 Aug 2013	2013	Q2
Q1 2012		$77,050			01 Jan 2012	31 Mar 2012	10-Q	15 May 2013	2013	Q1
Q3 2011		$132,812			01 Jul 2011	30 Sep 2011	10-Q	14 Nov 2012	2012	Q3
Q2 2011		$100,946			01 Apr 2011	30 Jun 2011	10-Q	14 Aug 2012	2012	Q2

Period	Value	YoY Chg	Change %	Start Date	End Date	Report	Filed	Fiscal Year	Fiscal Period
2013	$288,297	+$18,849	+7%	01 Jan 2013	31 Dec 2013	10-K	31 Mar 2014	2013	FY
2012	$269,448	-$176,463	-40%	01 Jan 2012	31 Dec 2012	10-K	31 Mar 2014	2013	FY
2011	$445,911			01 Jan 2011	31 Dec 2011	10-K	12 Mar 2013	2012	FY

* An asterisk sign (*) next to the value indicates that the value is likely invalid.